Effect of timing of gefitinib intake on blood levels of the drug in lung cancer patients
Not Applicable
- Conditions
- Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
- Registration Number
- CTRI/2021/09/036915
- Lead Sponsor
- Tavneet Kaur Makkar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1)Age >18 years irrespective of gender
2)Pathology confirmed NSCLC patients
3)EGFR sensitized mutation
4)Patients being planned to be started on gefitinib as a first line /maintenance /second line agent.
Exclusion Criteria
1)Patients not willing to participate in the study.
2)Patients on systemic steroids.
3)Patients in active uncontrolled pain/ severe distress not controlled on optimal analgesia.
4)Patients reporting disturbed sleep-wake cycle in last 7 days.
5)Patients with ECOG performance status >3
6)Known case of hepatic cirrhosis
7)Patients taking strong CYP3A4 inducers and inhibitors like rifampicin/ phenytoin/ ketoconazole/ itraconazole
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method